Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
PO
Pharma Operations Consulting & Development ApS
aktivCVR 45013197AnpartsselskabVed Dammen 2, 1, 2880 BagsværdAnden teknisk rådgivning
- Latest accounts
- 2025
- Statement scope
- Standalone
- Verified
- 06 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Data quality concern—
Data quality concern
Operating profit
DKK 238.2k
Latest period
Source details
Source: dk-regnskabsdata-live-45013197-1793926520742
Document: dk-regnskabsdata-45013197-AZxWP7slYmqIeOMz83LW-1
XBRL: d:ProfitLossFromOrdinaryOperatingActivities
Period: 13 Aug 2024 - 31 Dec 2025
Technical details
Context: c11
Unit: u3
Net result
DKK 185.1k
Latest period
Source details
Source: dk-regnskabsdata-live-45013197-1793926520742
Document: dk-regnskabsdata-45013197-AZxWP7slYmqIeOMz83LW-1
XBRL: d:ProfitLoss
Period: 13 Aug 2024 - 31 Dec 2025
Technical details
Context: c11
Unit: u3
Equity
DKK 225.1k
Equity ratio: 69.7%
Source details
Source: dk-regnskabsdata-live-45013197-1793926520742
Document: dk-regnskabsdata-45013197-AZxWP7slYmqIeOMz83LW-1
XBRL: d:Equity
Period: 13 Aug 2024 - 31 Dec 2025
Technical details
Context: c49
Unit: u3
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2024 | — | — |
| 2025 | — | DKK 185.1k |